Form submitted successfully. Thank you! Posters may be downloaded below. Please visit other areas of our site (noted below) to learn more.
|AACR session category name||Poster #||Title/Presenter|
|DNA Methylation||158||Custom primer design pipeline and analysis workflow for targeted methylation sequencing using NGS Ion AmpliSeq technology|
Presenter: Z. Luo
|Genomic Profiling of Tumors 1||170||Development and analytical validation of a novel next-generation DNA sequencing assay, the Oncomine Lymphoma Panel, to detect SNV, insertion, deletion and copy number variants in 25 Lymphoma genes in FFPE samples|
Presenter: F. Hyland
|177||RNA sequencing based gene fusion detection with Oncomine Comprehensive Assay Plus|
Presenter: A. Marcovitz
|179||Comprehensive genomic profiling of solid tumors for key targeted and immuno-oncology biomarkers using Ion Torrent NGS technology on the Oncomine Comprehensive Assay Plus (OCA Plus)|
Presenter: V. Mittal
|Large-Scale and High Throughput Sequencing||215||Oncomine Precision Assay - An Integrated and Automatic NGS Workflow for both FFPE Tissue and Plasma Based Cancer Research|
Presenter: R. Cao
|Predictive Biomarkers for Precision Medicine||772||Performance Characteristics of the Oncomine Dx Target Test for the Detection of IDH1 R132 Variants from Formalin-Fixed, Paraffin-Embedded (FFPE) Cholangiocarcinoma Samples|
Presenter: A. Aiyer
|Molecular Markers, Targets, and Microbiome||1164||A targeted next generation sequencing microbiome assay design|
Presenter: A. Ewing
|Genomics and Genetic Susceptibility||1207||Custom next-generation sequencing primer designs for targeted sequencing of multi strain viral targets|
Presenter: R. Singh
|Genomic Profiling of Tumors 2||1326||A novel system that produces pre-qualified cancer NGS panels with customizable content|
Presenter: S. Roman
|1330||Scalable single-day workflows for variant calling with the Genexus Integrated Sequencer|
Presenter: J. Gioia
|Genomic Profiling of Tumors 3||2505||The Oncomine BRCA extended next-generation sequencing assay: development and analytical validation of a new panel for detection of SNV, insertions, deletions and copy number variants in a panel of 15 gene involved in homologous recombination repair of double-strand break DNA damage|
Presenter: C. Scafe
|Circulating Markers 3||3118||Next generation sequencing assay for detection of gene fusions and exon deletion events in tissue and liquid biopsy samples at very low frequency|
Presenter: R. Gottimukkala
|Immune Monitoring / Clinical Correlates 1||3305||Comparative analysis of RNA versus DNA as input material for IGH repertoire sequencing based detection of rare clonal B cells at a frequency of 10E-6|
Presenter: M. Toro
Microbiome, Inflammation, and Cancer
|3347||Characterization of gut microbiota and identification of key bacterial species associated with immune response using a new Ion Torrent next-generation sequencing assay|
Presenter: S. Sarda
|Predictive Biomarkers for Treatment Efficacy 3||4279||Automated TRB locus haplotype analysis by long-amplicon TCRB chain sequencing for immune-related adverse events biomarker research|
Presenter: J. Burke
|Actionable Feature Detection in NGS and Omics||5472||Development of customizable targeted RNA fusion panels using a novel automated high-multiplexing primer design strategy|
Presenter: N. Li
|Prognostic Markers 2||6472||Clonal lineage and somatic hypermutation analysis of chronic lymphocytic leukemia by long-amplicon IGH chain sequencing|
Presenter: J. Chang
Scalable targeted NGS to support small and large projects
The Ion GeneStudio S5 system is a scalable, targeted-NGS workhorse with wide application breadth and throughput capability.
Specimen to report in a single day with a hands-off, automated workflow*
The Genexus System is the first turnkey NGS solution that automates the specimen-to-report workflow and delivers results in a single day with just two user touchpoints.*
Immuno-oncology therapies are considered to be promising anti-cancer treatments, generating excitement and hope among researchers, clinicians, and patients. The Ion Torrent portfolio of immuno-oncology assays uses the sensitivity of next-generation sequencing (NGS) to help researchers decipher the cancer-immunity cycle within precious samples.
One size doesn’t fit all.
We understand that not all labs are alike. NGS applications and content need to be tailored for your lab’s needs. A one-size-fits all approach just doesn’t work, so we’ve developed a range of Oncomine Assays to cover the spectrum of panel sizes and purposes. We listen and we create solutions for the way you work.
The Ion AmpliSeq Microbiome Health Research Kit is an NGS assay that allows for cost-effective yet comprehensive profiling of microbial diversity in the human gut microbiome. This new assay offers increased resolution and specificity of species-level detection compared with traditional 16S rRNA sequencing for key organisms associated with cancer, as well as immunological and gastrointestinal (GI) disorder research.
*Specimen-to-report workflow available after Ion Torrent Genexus Purification System and integrated report launch in 2020.